People with lactose intolerance may have decreased risk of breast, lung, and ovarian cancers
the ONA take:
According to a new study published in the journal Nature, researchers from Lung University and Region Skane in Sweden have found that people who are lactose intolerant have a decreased risk for developing breast, lung, and ovarian cancers.
For the study, researchers sought to investigate the possible association between dairy products and the development of cancer. To do so, they designed the study to determine whether low consumption of dairy products in people with lactose intolerance decreases their risk for developing breast, lung, and ovarian cancers.
The researchers identified nearly 23,000 individuals with lactose intolerance from two Swedish national registers. They found that the risks for developing any of the three cancers was significantly lower in people with lactose intolerance compared with to people without lactose intolerance. Incidence rates were similar across different genders and countries of birth.
The researchers also looked at the siblings and parents of those with lactose intolerance and found their risks for developing breast, lung, and ovarian cancers were similar to those of the general population. The findings suggest that patients with lactose intolerance may have a lower risk for those cancers as a result of their diet. The researchers note that the study does not prove cause and effect and further studies are warranted to explain this study's results.
People who are lactose intolerant have a decreased risk for developing breast, lung, and ovarian cancers.
Previous studies have shown that there are large differences in breast and ovarian cancer incidence across different areas of the globe. Experts know, for instance, that the highest incidence of breast and ovarian cancer is in North America, Western Europe and Scandinavia, while incidence is lowest in East and Central Africa.
Twin studies and studies of immigrants have suggested that these differences in incidence are due to environmental factors rather than genetic or ethnic differences.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|